Editas Medicine, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for EDIT, updated each market day.
EDIT AI Sentiment
AI predicts Editas Medicine, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Editas Medicine, Inc. Common Stock
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Sector
Exchange
Market Cap
$282,850,077
Cap Tier
Employees
87
Headquarters
CAMBRIDGE, MA
Listed Since
Feb. 3, 2016
Website
EDIT Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
EDIT Volatility
Editas Medicine, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
